This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Forward Step By Step With Action Plan 2016 - Continued Revenue Growth - Significant Pipeline Progress

The gross margin of the Group decreased to 35.6% (2011: 43.7%). The margin difference compared to 2011 is mainly attributable to a decrease in upfront payments, the ramp-up of capacities in EVT Execute, lower margin compound management revenues and the move into the new Manfred Eigen Campus at the start of 2012.

Evotec's operating result for 2012 amounted to € (3.2) m (2011: € 5.2 m), which primarily was due to a lower gross profit and an impairment of intangible assets in the amount of € 3.5 m (2011: € 0.6 m net of reversal of impairment). The impairment was mainly the result of the termination of the VR1 partnership with Pfizer. The operating result before impairment and changes in contingent consideration was positive at € 1.4 m (2011: € 5.8 m). Net income amounted to € 2.5 m (2011: € 6.7 m). The improvement in the net income primarily resulted from deferred tax income amounting to € 8.3 m (2011: € 2.5 m).

R&D expenditure amounted to € 8.3 m (2011: € 8.4 m). Evotec's unfunded research focused on selected discovery projects in the key areas of CNS, oncology, inflammation, metabolic and kidney disease such as the Cure Beta and Cure Nephron alliances with Harvard University.

Although there were significant investments in capital expenditures of € 8.2 m (2011: € 8.1 m) as well as in intangible assets and earn-out payments, the Company's liquidity position increased to € 64.2 m (2011: € 62.4 m), this is composed of cash and cash equivalents (€ 39.1 m) and of investments (€ 25.1 m). Therefore Evotec is very well-financed.

2. Evotec Action Plan 2016 – Step by step forward for higher Innovation Efficiency

Update on discovery alliances, development partnerships and status of pre-clinical programmes

Action Plan 2016 – Innovation Efficiency is the strategy framework that was initiated in March 2012. EVT Execute aims to deliver cost efficient and industrialised services for drug discovery on a fee-for-service basis. EVT Integrate is the systematic approach to progress targets through the pre-clinic, on a research payments, milestones and royalties success basis. EVT Innovate involves accelerating promising drug discovery ideas and assets to partnerships with upfront payments, premium research fees, milestones and royalties.

EVT Execute – Continued trend towards outsourcing services for biotech and Pharma; important new and extended collaborations

With CHDI, a privately funded not-for-profit research organisation dedicated to developing therapies for Huntington's disease (HD), Evotec extended its collaboration until the end of 2015. This contract extension could be worth up to $ 41 m in research payments for Evotec.

2 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs